X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
recist (689) 689
index medicus (656) 656
humans (654) 654
oncology (440) 440
female (424) 424
male (413) 413
middle aged (390) 390
aged (356) 356
solid tumors (349) 349
treatment outcome (344) 344
cancer (332) 332
radiology, nuclear medicine & medical imaging (324) 324
adult (273) 273
criteria (261) 261
chemotherapy (208) 208
tumors (203) 203
survival (187) 187
retrospective studies (169) 169
aged, 80 and over (162) 162
therapy (156) 156
care and treatment (149) 149
prognosis (148) 148
tomography, x-ray computed (141) 141
tumor response (138) 138
hepatocellular carcinoma (134) 134
modified recist (129) 129
antineoplastic agents - therapeutic use (128) 128
metastasis (124) 124
response evaluation criteria in solid tumors (120) 120
medicine & public health (117) 117
computed tomography (108) 108
positron-emission-tomography (106) 106
tomography, x-ray computed - methods (104) 104
reproducibility of results (101) 101
magnetic resonance imaging (98) 98
computed-tomography (97) 97
liver cancer (94) 94
patients (93) 93
sorafenib (90) 90
disease progression (89) 89
liver neoplasms - diagnostic imaging (89) 89
liver neoplasms - therapy (89) 89
radiology (89) 89
liver (88) 88
liver neoplasms - pathology (88) 88
analysis (87) 87
recist criteria (85) 85
response evaluation criteria (83) 83
article (81) 81
tumor burden (80) 80
neoplasm staging (79) 79
gastroenterology & hepatology (78) 78
liver neoplasms - drug therapy (77) 77
disease-free survival (76) 76
evaluation criteria (76) 76
research (76) 76
surgery (76) 76
carcinoma, hepatocellular - pathology (73) 73
carcinoma, hepatocellular - therapy (73) 73
guidelines (72) 72
diagnosis (70) 70
metastases (70) 70
sensitivity and specificity (69) 69
antineoplastic combined chemotherapy protocols - therapeutic use (68) 68
clinical trials (66) 66
imaging / radiology (66) 66
transarterial chemoembolization (66) 66
carcinoma (65) 65
ct imaging (65) 65
follow-up studies (65) 65
abridged index medicus (64) 64
contrast media (64) 64
response evaluation (64) 64
hematology, oncology and palliative medicine (62) 62
liver neoplasms - secondary (61) 61
management (61) 61
phase-ii (61) 61
survival rate (61) 61
hepatoma (59) 59
lesions (59) 59
prospective studies (59) 59
pet (56) 56
response criteria (56) 56
hepatocellular-carcinoma (55) 55
kaplan-meier estimate (55) 55
positron-emission tomography (54) 54
carcinoma, hepatocellular - diagnostic imaging (53) 53
respiratory system (53) 53
radiotherapy (52) 52
carcinoma, hepatocellular - drug therapy (51) 51
lung neoplasms - drug therapy (51) 51
lung neoplasms - pathology (50) 50
development and progression (49) 49
lung cancer (49) 49
medical imaging (49) 49
mri (49) 49
cell lung-cancer (48) 48
imatinib mesylate (48) 48
lung neoplasms - diagnostic imaging (48) 48
algorithms (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (977) 977
German (30) 30
French (16) 16
Japanese (12) 12
Spanish (6) 6
Korean (5) 5
Czech (2) 2
Polish (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 82, pp. 27 - 33
Journal Article
Journal Article
European Journal of Radiology, ISSN 0720-048X, 2016, Volume 85, Issue 8, pp. 1445 - 1452
Journal Article
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2011, Volume 59, Issue 5, pp. 856 - 862
Abstract Background Vascular endothelial growth factor (VEGF)-targeted therapy has become standard treatment for patients with metastatic renal cell cancer... 
Urology | Tumor shrinkage | VEGF-targeted therapy | RECIST 1.0 | Renal cell carcinoma | Choi | RESPONSE CRITERIA | SIZE | CANCER | ANTIANGIOGENIC THERAPY | CONTRAST-ENHANCED CT | ATTENUATION | SUNITINIB | UROLOGY & NEPHROLOGY | Niacinamide - analogs & derivatives | Predictive Value of Tests | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Tomography, X-Ray Computed | Benzenesulfonates - therapeutic use | Kidney Neoplasms - metabolism | Phenylurea Compounds | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Molecular Targeted Therapy | Bevacizumab | Antibodies, Monoclonal, Humanized | Time Factors | Angiogenesis Inhibitors - therapeutic use | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Boston | Pyridines - therapeutic use | Reproducibility of Results | Carcinoma, Renal Cell - diagnostic imaging | Carcinoma, Renal Cell - pathology | Kaplan-Meier Estimate | Treatment Outcome | Academic Medical Centers | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - metabolism | Carcinoma, Renal Cell - mortality | Kidney Neoplasms - diagnostic imaging | Tumor Burden - drug effects | Indoles - therapeutic use | Kidney Neoplasms - pathology | ROC Curve | Kidney Neoplasms - drug therapy | Neoplasm Staging | Observer Variation | Medical research | Medical colleges | CT imaging | Care and treatment | Patient outcomes | Medicine, Experimental | Carcinoma, Renal cell | Comparative analysis | Vascular endothelial growth factor | Cancer | Statistical analysis | Population studies | Thorax | Survival | Kidney | Metastases | Necrosis | Atrophy | renal cell carcinoma | Computed tomography | Solid tumors | Tumors
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 03/2019, Volume 60, Issue 3, pp. 328 - 334
The optimal methodology for defining response with F-18-FDG PET after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown. We... 
Peter Mac | FDG-PET | RECIST | NSCLC | EORTC | PATHOLOGICAL RESPONSE | FDG PET/CT | SOLID TUMORS PERCIST | CHEMOTHERAPY | RADICAL RADIOTHERAPY | POSITRON-EMISSION-TOMOGRAPHY | THERAPY | PERCIST | SUPERIOR | Deauville criteria | OUTCOMES | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Journal Article